Fully Human Antibodies Targeting CCR2 Receptor for Inflammatory Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CCR2-mediated disorders, such as autoimmune diseases and inflammatory conditions, lack effective therapeutic agents that specifically target the CCR2 receptor, leading to inadequate management of conditions like atherosclerosis, rheumatoid arthritis, and asthma.
Innovation Solution
Development of fully human antibodies, antibody fragments, and single-chain antibodies that bind to the CCR2 receptor with high affinity, specifically targeting the receptor to inhibit its interaction with chemokines like MCP-1, thereby reducing inflammation and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for CCR2-mediated disorders, then general anti-inflammatory effects are achieved, but specific targeting of CCR2 receptor is lacking leading to inadequate therapeutic management
Solution Approach 1:
The patent introduces fully human antibodies (such as D1, 1G11, 1B2, 1H5) as intermediary molecules that specifically bind to the CCR2 receptor. These antibodies act as mediators between the therapeutic goal and the target receptor, providing precise and reliable inhibition of CCR2-mediated pathways without the lack of specificity inherent in conventional treatments.
2Reliability
If fully human antibodies are developed to specifically bind CCR2, then high affinity and specificity are achieved, but complexity of antibody development and production increases
Solution Approach 1:
The patent employs phage display technology and humanized antibody frameworks that allow the antibody sequences to self-select and self-optimize for high-affinity binding to CCR2. The combinatorial library approach enables the system to autonomously identify and produce fully human antibodies with optimal binding characteristics, reducing the need for extensive manual engineering and simplifying the development process despite the high specificity requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These antibodies effectively reduce inflammation and immune responses, providing therapeutic benefits in treating a broad spectrum of CCR2-mediated disorders, including autoimmune diseases and inflammatory conditions, by specifically targeting the CCR2 receptor.
Implementation Method 1
fully human antibodies, antibody fragments, and single-chain antibodies that bind to the CCR2 receptor with high affinity
Data Source
AI summary
There is disclosed compositions and methods relating to or derived from anti-CCR2 antibodies. More specifically, there is disclosed fully human antibodies that bind CCR2, CCR2-binding fragments and derivatives of such antibodies, and CCR2-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CCR2 related disorders or conditions.